vTv Therapeutics Inc.

vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized;…